

# Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease

Jennie L. Davis, DO, Julie A. Kurek, MD, John C. Morgan, MD, PhD, and Kapil D. Sethi, MD, FRCP

*Neurology*® 2018;90:e263. doi:10.1212/WNL.0000000000004816

## Correspondence

Dr. Davis  
Jennie\_Davis@valleymed.org

A 52-year-old woman with Parkinson disease (PD) since age 42 on carbidopa/levodopa 25/250 5 times/d developed “offs” characterized by left foot dystonia. After adding rasagiline 1 mg/d, multihour episodes of gaze deviation, anxiety, retrocollis, and dyskinesias ensued (video, [links.lww.com/WNL/A30](https://links.lww.com/WNL/A30)). Symptoms, marginally improved with diphenhydramine, resolved when levodopa was held temporarily. They did not recur after discontinuation of rasagiline.

Typical oculogyric crisis lasting hours with accompanying psychiatric features is rare in PD.<sup>1,2</sup> It is more commonly associated with dopamine blockers, postencephalitic parkinsonism, and disorders of dopamine metabolism.<sup>1</sup> Levodopa-induced brief suppressible gaze deviation, toward the side most affected in advanced PD, is more prevalent.<sup>2</sup>

## Author contributions

Jennie Davis: study concept and design, acquisition of data, drafting and critical revision of manuscript for intellectual content. Julie Kurek: study concept and design, critical revision of manuscript for intellectual content. John Morgan: study concept and design, acquisition of data, critical revision of manuscript for intellectual content. Kapil Sethi: study concept and design, critical revision of manuscript for intellectual content.

## Study funding

No targeted funding reported.

## Disclosure

J. Davis reports no disclosures relevant to the manuscript. J. Kurek received speaker’s honoraria from Teva. J. Morgan: consultant to Acorda, Impax, Lundbeck, Teva, Veloxis, and the National Parkinson’s Foundation; speaker for Impax and Teva; research support from NIH and National Parkinson’s Foundation; expert witness and consultant in various neurologic legal cases. K. Sethi: past employment: Merz Pharmaceuticals; consultant for Cynapsus and Teva Grant; support from the NIH, National Parkinson’s Foundation, Kyowa, AbbVie, Acadia, Biotie, and Serina; expert witness in welding and metoclopramide litigation. Go to [Neurology.org](https://Neurology.org) for full disclosures.

## References

1. Slow EJ, Lang AE. Oculogyric crises: a review of phenomenology, etiology, pathogenesis, treat. *Mov Disord* 2017;32:193–202.
2. Grotzsch H, Sztajzel R, Burkhard PR. Levodopa-induced ocular dyskinesia in Parkinson’s disease. *Eur J Neurol* 2007;14:1124–1128.

## MORE ONLINE

### Video

[links.lww.com/WNL/A30](https://links.lww.com/WNL/A30)

### Teaching slides:

[links.lww.com/WNL/A223](https://links.lww.com/WNL/A223)

From the Neuroscience Institute (J.L.D.), University of Washington-Valley Medical Center, Renton; and Movement Disorders Program, Department of Neurology (J.A.K., J.C.M., K.D.S.), Augusta University, Georgia.

Go to [Neurology.org/N](https://Neurology.org/N) for full disclosures.

# Neurology®

## Teaching Video NeuroImages: Oculogyric crisis in treated Parkinson disease

Jennie L. Davis, Julie A. Kurek, John C. Morgan, et al.

*Neurology* 2018;90:e263

DOI 10.1212/WNL.0000000000004816

**This information is current as of January 15, 2018**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/90/3/e263.full">http://n.neurology.org/content/90/3/e263.full</a>
<b>References</b>	This article cites 2 articles, 0 of which you can access for free at: <a href="http://n.neurology.org/content/90/3/e263.full#ref-list-1">http://n.neurology.org/content/90/3/e263.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Parkinson's disease/Parkinsonism</b> <a href="http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism">http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

